Strauss Borrelli PLLC, a leading data breach law firm, is investigating Taro Pharmaceuticals U.S.A., Inc. regarding its recent data breach. The Taro Pharmaceuticals U.S.A. data breach involved sensitive personal identifiable information belonging over 1,700 current and former employees.
ABOUT TARO PHARMACEUTICALS U.S.A., INC.:
Taro Pharmaceuticals U.S.A., a subsidiary of Sun Pharmaceutical Industries, Inc., is a pharmaceutical research company specializing in over-the-counter pharmaceutical products. As a pharmaceutical manufacturing company, Taro Pharmaceuticals U.S.A. produces topical dermatological products as well as cardiology and neurology medications. Headquartered in the United States, Taro Pharmaceuticals U.S.A. has research and manufacturing facilities in Haifa, Israel and Brampton, Canada. Serving markets in over 25 countries, Taro Pharmaceuticals U.S.A. has more than 180 pharmaceutical products sold across the world. Taro Pharmaceuticals U.S.A. is a publicly traded company valued at approximately $900 million.
WHAT HAPPENED?
On March 25, 2023, Taro Pharmaceuticals U.S.A. discovered that it had experienced a data breach in which the sensitive personal identifiable information in its systems may have been accessed. Through its investigation, Taro Pharmaceuticals U.S.A. determined that an unauthorized actor may have accessed this sensitive information on March 3, 2023. On April 19, 2023, Taro Pharmaceuticals U.S.A. began contacting individuals whose information may have been impacted. The type of information exposed includes:
- Name
- Social Security number
- Driver’s license number
- Passport number
If you received a breach notification letter from Taro Pharmaceuticals U.S.A., Inc. or Sun Pharmaceutical Industries, Inc.:
We would like to speak with you about your rights and potential legal remedies in response to this data breach. Please fill out the form, below, or contact us at 872.263.1100 or sam@straussborrelli.com.
